{'fraction_non_alphanumeric': 0.046094750320102434, 'fraction_numerical': 0.03329065300896287, 'mean_word_length': 4.283783783783784, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Methotrexate on a 21-day cycle for low-risk gestational trophoblastic neoplasia.

OBJECTIVE
To perform an outcome analysis of patients with low-risk gestational trophoblastic neoplasia (GTN) treated with a 5-day intramuscular methotrexate (MTX) regimen on a 21-day cycle.


STUDY DESIGN
A retrospective review of 31 patients with low-risk GTN treated with a 5-day MTX regimen.


RESULTS
A total of 31 patients with low-risk GTN (WHO score < 7) received single-agent MTX at a dose of 0.4 mg/kg daily for 5 days every 21 days (mean number of cycles, 3; 83% remission). The only significant toxicity encountered was grade 2 stomatitis in 8 (26%) patients.


CONCLUSION
A 5-day MTX regimen given every 21 days is convenient, well-tolerated and effective for patients with low-risk GTN.